{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:31:12Z","timestamp":1792197072197,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.yebeh.2022.108954","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T08:19:03Z","timestamp":1668154743000},"page":"108954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["Double antiglutamatergic treatment in patients with status epilepticus: A case series"],"prefix":"10.1016","volume":"137","author":[{"given":"Hassan","family":"Souidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene Andrade","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhamid","family":"Lagnf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.yebeh.2022.108954_b0005","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.2174\/1381612043382846","article-title":"Propofol: therapeutic indications and side-effects","volume":"10","author":"Marik","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"Suppl 8","key":"10.1016\/j.yebeh.2022.108954_b0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2011.03234.x","article-title":"Anesthestic agents and status epilepticus","volume":"52","author":"Smith","year":"2011","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108954_b0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108954_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108954_b0025","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"667","key":"10.1016\/j.yebeh.2022.108954_b0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neulet.2016.12.044","article-title":"Pathophysiology of status epilepticus","volume":"22","author":"Walker","year":"2018","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108954_b0035","doi-asserted-by":"crossref","first-page":"e00063","DOI":"10.1002\/prp2.63","article-title":"Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model","volume":"2","author":"Hanada","year":"2014","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"10.1016\/j.yebeh.2022.108954_b0040","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40263-018-0569-6","article-title":"Ketamine for refractory status epilepticus: a systematic review","volume":"32","author":"Rosati","year":"2018","journal-title":"CNS Drugs"},{"issue":"16","key":"10.1016\/j.yebeh.2022.108954_b0045","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.1212\/WNL.0000000000010611","article-title":"Ketamine to treat super-refractory status epilepticus","volume":"95","author":"Alkhachroum","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108954_b0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.yebeh.2015.06.019","article-title":"Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation","volume":"49","author":"Ilvento","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108954_b0055","doi-asserted-by":"crossref","first-page":"108512","DOI":"10.1016\/j.yebeh.2021.108512","article-title":"The role of ketamine-induced beta activity in the treatment of refractory status epilepticus. Is the EEG useful to determine responder's rate? A retrospective study","volume":"127","author":"Machado","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108954_b0060","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108954_b0065","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/jcmm.16426","article-title":"Neuroprotective effect of ketamine against TNF-\u03b1-induced necroptosis in hippocampal neurons","volume":"25","author":"Wang","year":"2021","journal-title":"J Cell Mol Med"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:48:26Z","timestamp":1761504506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022004036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":13,"alternative-id":["S1525505022004036"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108954","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double antiglutamatergic treatment in patients with status epilepticus: A case series","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108954"}}